Login to Your Account

Haiyan Pharmaceutical Technology is a little R&D fish in the biggest sea

By Shannon Ellis
Staff Writer

Wednesday, June 4, 2014

SHANGHAI – It is no secret that China is heavy on generics and light on innovation. But what happens when a successful drug maker with deep pockets and a visionary chairman decide to take on drug discovery? Haiyan Pharmaceutical Technology Co. Ltd., the drug development subsidiary of the Yangtze River Pharmaceutical Group (YRP), and its team of executive returnees are set to prove that innovation can be implanted anywhere, even in a risk adverse generics maker.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription